BioSpace News Archive

XOMA Corporation (NASDAQ: XOMA), announced today NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation in pancreatic cancer by the U.S. Food and Drug Administration.

M6P Therapeutics (“M6PT” or “the Company”), today announced pre-clinical proof-of-concept data on M041 in a poster presentation by Patricia Dickson, M.D., Centennial Professor of Pediatrics and Chief, Division of Genetics and Genomic Medicine, Washington University of St. Louis, titled “Recombinant human NAGLU with improved mannose 6-phosphorylation for Sanfilippo B syndrome” at the 16th Annual International Symposium of MPS and Related Diseases (“MPS 2021”).

TRACON Pharmaceuticals (NASDAQ:TCON), announced today that it will report its second quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, August 11, 2021.

ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that the paper entitled “Bucindolol [Gencaro] Decreases AF Burden” (Jonathan Piccini, et al), which details a new analysis of the Gencaro Phase 2b data on atrial fibrillation (AF) burden and rhythm control interventions has been published in Circulation: Arrhythmia and Electrophysiology, a journal of the American Heart Association

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced preliminary XHANCE® net product revenue of $18.4 million for the three months ended June 30, 2021.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced today that its management team will present at several investor conferences listed below during the third quarter of 2021.

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today provided a clinical trial update on Tigris, a follow on study designed to build on knowledge gained from the earlier EUPHRATES trial, evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Portage Biotech Inc. a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, announced financial results for the fiscal year ended March 31, 2021.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) clearance for two AccuRhythm™ AI algorithms for use with the LINQ II™ insertable cardiac monitor (ICM).

owing to its efficiency in product management and cost-effectiveness. Healthcare equipment leasing is considered as a cost-effective alternative for acquiring capital medical equipment.